Eli Lilly and Company (NYSE:LLY) Stock Rated "Moderate Buy" by Wall Street Brokerages

Key Points

• Analysts remain bullish: Thirty brokerages give Eli Lilly a consensus “Moderate Buy” rating, with 25 buys and an average 12-month price target of $1,313.43.
• Strong financial results: The company reported quarterly EPS of $8.38 versus expectations of $6.40, while revenue rose 47.7% year over year to $22.97 billion.
• Growth catalysts and risks: Continued demand for diabetes and obesity medicines could support higher guidance, while promising Taltz-Zepbound data expand Lilly’s opportunity; however, higher treatment discontinuation rates and recent insider selling remain concerns.

Eli Lilly and Company (NYSE:LLY - Get Free Report) has been given a consensus rating of "Moderate Buy" by the thirty ratings firms that are covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, twenty-five have assigned a buy rating and one has issued a strong buy rating on the company. The average 12-month price target among brokerages that have covered the stock in the last year is $1,313.43.

LLY has been the subject of several recent research reports. Truist Financial boosted their price target on shares of Eli Lilly and Company from $1,370.00 to $1,376.00 and gave the company a "buy" rating in a report on Friday, August 7th. The Goldman Sachs Group increased their price objective on shares of Eli Lilly and Company from $1,367.00 to $1,371.00 and gave the company a "buy" rating in a research note on Thursday, September 17th. UBS Group set a $1,376.00 price objective on shares of Eli Lilly and Company in a research note on Friday, August 7th. Cantor Fitzgerald upped their target price on Eli Lilly and Company from $1,410.00 to $1,440.00 and gave the stock an "overweight" rating in a report on Thursday, October 8th. Finally, HSBC upped their price objective on Eli Lilly and Company from $850.00 to $940.00 and gave the stock a "reduce" rating in a research note on Thursday, September 10th.

Eli Lilly and Company Stock Performance

LLY stock opened at $1,183.51 on Tuesday. Eli Lilly and Company has a 1-year low of $783.85 and a 1-year high of $1,292.65. The business has a 50-day moving average price of $1,175.57 and a 200 day moving average price of $1,100.31. The company has a market capitalization of $1.11 trillion, a P/E ratio of 39.72, a PEG ratio of 1.47 and a beta of 0.46. The company has a debt-to-equity ratio of 1.41, a current ratio of 1.35 and a quick ratio of 1.00.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.40 by $1.98. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. The company had revenue of $22.97 billion for the quarter, compared to analysts' expectations of $20.82 billion. During the same period in the prior year, the business earned $6.31 EPS. The firm's quarterly revenue was up 47.7% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. As a group, equities research analysts forecast that Eli Lilly and Company will post 36.19 EPS for the current fiscal year.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Potentially higher revenue guidance: RBC said Lilly could raise its full-year revenue outlook, citing continued momentum for its diabetes and weight-loss products. Eli Lilly Likely to Raise Revenue Outlook Amid Strong Diabetes, Weight-Loss Drug Sales
• Positive Sentiment: Positive analyst view: Royal Bank of Canada reiterated its “Outperform” rating and maintained a $1,500 price target, implying significant upside from the recent trading level. Eli Lilly and Company's Outperform Rating Reiterated at Royal Bank Of Canada
• Positive Sentiment: Encouraging Taltz-Zepbound data: New Phase 3b results showed that combining Taltz with Zepbound produced greater skin clearance and weight loss than standard treatment in adults with plaque psoriasis and obesity. The results may support a broader immunometabolic treatment opportunity for Lilly. Lilly reports Phase IIIb data on Taltz and Zepbound combination
• Positive Sentiment: Demand remains visible: Illicit online sales of investigational retatrutide before launch underscore strong interest in Lilly’s next-generation obesity candidate, although the activity also creates counterfeit-drug and regulatory risks. Lilly is fighting a black market for its new obesity drug even before it launches
• Neutral Sentiment: Recent pullback viewed as profit-taking: Commentary characterized Lilly’s recent retreat as a normal pause following a strong run rather than evidence that demand for its GLP-1 medicines or the long-term growth thesis has deteriorated. Eli Lilly Stock Has Pulled Back 8%. History Says This Is What Happens Next.
• Negative Sentiment: Combination-treatment risk: Although Taltz plus Zepbound generated more weight loss than Zepbound alone, discontinuation rates were also substantially higher, potentially limiting real-world adoption unless tolerability improves. This Drug Combination for Eli Lilly Generated Significantly More Weight Loss Than Just Zepbound

Insider Transactions at Eli Lilly and Company

In related news, CAO Donald Zakrowski sold 2,000 shares of the business's stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $1,185.01, for a total transaction of $2,370,020.00. Following the completion of the transaction, the chief accounting officer owned 1,526 shares in the company, valued at $1,808,325.26. The trade was a 56.72% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of the stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $1,190.00, for a total transaction of $5,950,000.00. Following the sale, the executive vice president directly owned 11,875 shares of the company's stock, valued at $14,131,250. The trade was a 29.63% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 13,500 shares of company stock valued at $15,958,170 in the last 90 days. Insiders own 0.14% of the company's stock.

Hedge Funds Weigh In On Eli Lilly and Company

Large investors have recently made changes to their positions in the business. Osbon Capital Management LLC purchased a new position in shares of Eli Lilly and Company in the fourth quarter worth $25,000. Basso Capital Management L.P. acquired a new stake in shares of Eli Lilly and Company during the fourth quarter worth $30,000. Maseco LLP grew its holdings in shares of Eli Lilly and Company by 466.7% during the first quarter. Maseco LLP now owns 34 shares of the company's stock valued at $31,000 after buying an additional 28 shares during the last quarter. Gunpowder Capital Management LLC dba Oliver Wealth Management purchased a new stake in shares of Eli Lilly and Company during the fourth quarter valued at $39,000. Finally, Aventus Investment Advisors Inc. grew its holdings in shares of Eli Lilly and Company by 270.0% during the first quarter. Aventus Investment Advisors Inc. now owns 37 shares of the company's stock valued at $34,000 after buying an additional 27 shares during the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

Eli Lilly and Company Company Profile

Eli Lilly and Company is a global pharmaceutical company headquartered in Indianapolis, Indiana. Founded in 1876 by Colonel Eli Lilly, the company researches, develops, manufactures and markets medicines for a range of conditions, including diabetes, obesity, cancer, immunological disorders, neurological diseases and pain.

Its products include Mounjaro and Zepbound, which contain tirzepatide and are used for type 2 diabetes and chronic weight management, respectively. Other key medicines include Trulicity for diabetes, Verzenio for certain breast cancers, Taltz for inflammatory and autoimmune conditions, Humalog insulin, and Kisunla for early symptomatic Alzheimer's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.